IRC
AZN icon

Investors Research Corp’s AstraZeneca AZN Stock Holding History

Investors Research Corp’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$97.9K Sell
606
-36
-6% -$6K 0.02% 332
2026
Q2 		$122K Buy
+642
New +$121K 0.02% 310
2026
Q1 		– Sell
-1,240
Closed -$228K – 853
2025
Q4 		$228K Hold
1,240
– – 0.04% 280
2025
Q3 		$190K Buy
1,240
+110
+10% +$16.6K 0.04% 307
2025
Q2 		$158K Hold
1,130
– – 0.03% 331
2025
Q1 		$166K Buy
1,130
+120
+12% +$17.4K 0.04% 316
2024
Q4 		$132K Hold
1,010
– – 0.03% 354
2024
Q3 		$157K Hold
1,010
– – 0.03% 340
2024
Q2 		$158K Sell
1,010
-577
-36% -$86.8K 0.04% 339
2024
Q1 		$215K Sell
1,587
-392
-20% -$51.9K 0.05% 312
2023
Q4 		$267K Buy
1,979
+192
+11% +$25K 0.06% 285
2023
Q3 		$242K Hold
1,787
– – 0.06% 296
2023
Q2 		$256K Sell
1,787
-1,200
-40% -$177K 0.06% 298
2023
Q1 		$415K Sell
2,987
-350
-10% -$47.1K 0.11% 235
2022
Q4 		$452K Hold
3,337
– – 0.12% 219
2022
Q3 		$366K Buy
3,337
+15
+0.5% +$1.9K 0.11% 226
2022
Q2 		$439K Hold
3,322
– – 0.13% 213
2022
Q1 		$441K Hold
3,322
– – 0.12% 210
2021
Q4 		$387K Hold
3,322
– – 0.12% 215
2021
Q3 		$399K Buy
3,322
+322
+11% +$37.5K 0.13% 204
2021
Q2 		$359K Hold
3,000
– – 0.12% 219
2021
Q1 		$298K Hold
3,000
– – 0.11% 245
2020
Q4 		$300K Hold
3,000
– – 0.12% 241
2020
Q3 		$329K Hold
3,000
– – 0.16% 190
2020
Q2 		$317K Hold
3,000
– – 0.16% 200
2020
Q1 		$268K Hold
3,000
– – 0.17% 210
2019
Q4 		$299K Sell
3,000
-833
-22% -$78.4K 0.14% 230
2019
Q3 		$342K Hold
3,833
– – 0.17% 182
2019
Q2 		$316K Sell
3,833
-150
-4% -$11.8K 0.17% 187
2019
Q1 		$322K Hold
3,983
– – 0.17% 180
2018
Q4 		$303K Hold
3,983
– – 0.21% 179
2018
Q3 		$315K Hold
3,983
– – 0.18% 200
2018
Q2 		$280K Hold
3,983
– – 0.16% 217
2018
Q1 		$279K Hold
3,983
– – 0.17% 225
2017
Q4 		$276K Buy
+3,983
New +$269K 0.17% 217

Other funds holding AZN

AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $837M AUM 20.44% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return
PNC
Park National Corp Newark, Ohio $3.69B AUM 18.32% 1-Year Est. Return
CCM
Cox Capital Management Andover, Massachusetts $179M AUM 28.94% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CNBT
Canandaigua National Bank & Trust Canandaigua, New York $1.15B AUM
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
PC
Parrish Capital Kennesaw, Georgia $103M AUM 35.11% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Investors Research Corp's AZN Position: Q3 2026 in Review

Investors Research Corp reduced its AstraZeneca (AZN) stake by 5.6% in Q3 2026, selling an estimated $6K and leaving 606 shares worth $97.9K. The position accounts for 0.02% of the portfolio, ranked #332.

Investors Research Corp first reported a position in AZN in Q4 2017 and has held it in 35 quarters since. The position peaked at $452K in Q4 2022. 47 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Investors Research Corp held 606 shares of AstraZeneca worth $97.9K as of Q3 2026.
  • Investors Research Corp sold 36 AstraZeneca shares in Q3 2026, an estimated $6K.
  • AstraZeneca made up 0.02% of Investors Research Corp's portfolio in Q3 2026, its #332 holding.
  • Investors Research Corp first reported a position in AstraZeneca in Q4 2017 and has held it in 35 quarters since.
  • Investors Research Corp's AstraZeneca position peaked at $452K in Q4 2022.
  • 47 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Investors Research Corp's 13F filing for Q3 2026, filed 7 Oct 2026.